Navigation Links
Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
Date:3/12/2013

VANCOUVER, British Columbia, March 12, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp (OTC PINK: ATTBF) (CNSX: FLU) today announced that it has provided $10,000 sponsorship for the cannabis (cannabis sp.) monograph and therapeutic compendium currently under development by the American Herbal Pharmacopoeia (AHP).

The monograph, scheduled for release in Spring 2013, will provide industry with a variety of scientifically valid analytical methods suitable for use in the identification, purity, and quality assessment of cannabis and its crude products.

Health Canada has recently proposed changes to the Canada's Marijuana Medical Access Program that aims to treat marijuana as it does any prescribed drug, allowing for legal commercial production for those who meet specific requirements.

"This generous sponsorship from Abattis Bioceuticals will facilitate the completion of this important and timely monograph," said Roy Upton , executive director of AHP.  "There is a critical need for quality controls to be put in place in the cannabis industry to ensure valid and appropriate testing methodologies, and the AHP monograph will help to create greater transparency and establish standard methods of analysis."

"We are extremely proud to support the development of this monograph by AHP," said Mr. Michael Withrow , Abattis' chief executive officer. He went on to say, "There is a strong need for the development of transparent standards for cannabis and its products and an incredible need for objective and critical review of the therapeutic and safety data on cannabis, especially now as the laws are being changed to allow for multiple uses of this misunderstood botanical. The world needs standards for Cannabis and the many phytochemicals that come from it so lawmakers can properly categorize them and so formulators can legally apply the compounds in appropriate products that help those who are suffering from various chronic diseases."

About Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp., based in Langley, B.C., is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of growing, producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in the pharmaceuticals, nutraceuticals, cosmetics, and animal nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high-growth areas of functional foods and dietary supplements business. For more information, visit the company's website at www.abattis.com.

About the American Herbal Pharmacopoeia

The American Herbal Pharmacopoeia is a non-profit 501C(3), California-based research organization with a mission to promote the responsible use of herbal products and herbal medicines through the production of critically reviewed monographs that outline the quality control criteria needed for ensuring the identity, purity, and quality of botanical raw materials. Founded in 1995, AHP has monographs on 35 different botanicals. For more information, visit AHP's website, http://www.herbal-ahp.org/index.html.

ON BEHALF OF THE BOARD

" Michael Withrow "
Michael Withrow , President & CEO

Mr. Mike Withrow

778-896-6536

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements.  These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances.  In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control.  There can be no assurance that any forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.  Accordingly, readers should not place undue reliance on forward-looking statements.  Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or to revise them to reflect the occurrence of future unanticipated events.


'/>"/>
SOURCE Abattis Bioceuticals Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
2. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
4. NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
5. Medical Alarm Concepts Provides Investor Update - Signs Deal with Health Care Insurance Provider for Medical Alarms
6. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
7. Compass Diversified Holdings Provides Shareholders with 2012 Tax Information
8. Volcano Corporation Provides Additional Guidance For 2013
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
10. AcelRx Pharmaceuticals Provides Clinical Trial Updates
11. Masimo Reports Fourth Quarter and Full Year 2012 Financial Results; Provides 2013 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 Research ... Electrophoresis Market 2017-2021" report to their offering. ... The global capillary electrophoresis market ... The report, Global Capillary Electrophoresis Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/23/2017)... -- CENTRO DE IMAGEM DIAGNOSTICOS S.A. (" Company "), ... 6,404/76 and Instruction 358/02 of the Brazilian Securities and ... market in general that it entered yesterday, as a ... Imagem Ltda. (" CDI "), into an agreement for ... (" Partnership " and " Acquisition "). ...
(Date:3/23/2017)... -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company ... unmet medical needs in rare diseases, today announced that ... on Monday, April 3 during ENDO 2017, the annual ... Florida , to discuss new data regarding its ... PTH and TransCon CNP). Ascendis is presenting ...
Breaking Medicine Technology:
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... and individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT to ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware of the ... do not brush their teeth the minimum two times a day that dentists recommend. The ... missing 51 million hours of school and adults missing 164 million hours of work each ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):